Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer-Reference-Cited by-同舟云学术

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer

Published:2011-10-12 Issue:2 Volume:109 Page:183-188
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

van der Sluis Tim M.,Meuleman Eric J.H.,van Moorselaar R. Jeroen A.,Bui Hong N.,Blankenstein Marinus A.,Heijboer Annemieke C.,Vis André N.

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2011.10652.x/fullpdf

Reference28 articles.

1. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group;Soloway;Urology,1991

2. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma;Peeling;Urology,1989

3. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia;McConnell;J Clin Endocrinol Metab,1992

4. Androgen metabolism in men receiving finasteride before prostatectomy;Norman;J Urol,1993

5. Selectivity of finasteride as an in vivo inhibitor of 5- alpha reductase isoenzyme activity in the human prostate;Span;J Urol,1999

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated periprostatic androgens, sneaky testosterone and its implications;Nature Reviews Urology;2024-05-07

2. Androgen Receptor Expression In Benign Prostatic Hyperplasia And Prostate Cancer;Journal of Population Therapeutics and Clinical Pharmacology;2023-01-01

3. Testosterone and the Androgen Receptor;Urologic Clinics of North America;2022-11

4. Hypogonadism and urologic surgeries: a narrative review;Translational Andrology and Urology;2022-07

5. Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia;International Journal of Cancer;2022-06-07